{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"401","value":"336"},{"groupId":"OG001","lowerLimit":"91","upperLimit":"152","value":"112"},{"groupId":"OG002","lowerLimit":"28","upperLimit":"56","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Median and range of nine patients with Complete Response (CR)","dispersionType":"Full Range","groups":[{"description":"Patients receive 20 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm 1: 20 mg Leflunomide"},{"description":"Patients receive 40 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm 2: 40 mg Leflunomide"},{"description":"Patients receive 60 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Arm 3: 60 mg Leflunomide"}],"paramType":"MEDIAN","populationDescription":"Among the 12 enrolled patients, only 11 patients are evaluable for response. And 9 of the 11 evaluable patients reached CR. The response duration is based on these 9 CR patients.","reportingStatus":"POSTED","timeFrame":"Assessed up to 48 months","title":"Response Duration","type":"SECONDARY","unitOfMeasure":"days"}